- Home
- ERAS
ERAS
Erasca Inc.
as 12-18-2024 12:36pm EST
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 723.8M | IPO Year: | 2021 |
| Target Price: | $5.90 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $3.45 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Erasca Inc. News
ERAS Breaking Stock News: Dive into ERAS Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Jefferies Initiates Erasca at Buy With $6 Price Target
Zacks
a month ago
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
a month ago
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
GlobeNewswire
a month ago
Erasca to Present at Upcoming Investor Conferences
Simply Wall St.
2 months ago
Erasca Insiders Added US$1.95m Of Stock To Their Holdings
GlobeNewswire
2 months ago
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
GlobeNewswire
3 months ago
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Simply Wall St.
3 months ago
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company
Compare ERAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERAS Erasca Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.